CRDL — Cardiol Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1702123 ·
Last close
$0.97
Market Cap
$113.53M
52W High
$2.34
52W Low
$0.88
ADV30
798,230
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -9,801,999 | -13,324,604 | 32,885,787 | 29,229,802 | 5,282,533 |
| Jun 2026 | 0 | — | -7,937,921 | -6,081,827 | 29,357,847 | 26,081,066 | 5,328,926 |
| Mar 2026 | 0 | — | -9,706,794 | -10,818,589 | 31,406,607 | 27,673,191 | 7,203,302 |
| Dec 2025 | 0 | — | -8,030,975 | -7,212,569 | 23,619,933 | 21,416,684 | 5,742,215 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,047,119
Investing CF
$-56,720
Financing CF
$31,610,015
CapEx
$-56,720
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.37
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-229,973,391
Inventory
—
Receivables
$312,611
ST Investments
—
EBIT TTM
$-35,855,790
Pretax Income TTM
$-34,077,266
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,316,296 | -33,818,874 | 23,619,933 | 5,742,215 | 17,877,718 | -23,854,650 |
| Dec 2024 | 0 | -40,276,651 | -36,677,299 | 31,863,751 | 7,135,268 | 24,728,483 | -25,060,867 |
| Dec 2023 | 0 | -29,785,504 | -28,128,292 | 36,700,508 | 8,454,001 | 28,246,507 | -25,180,441 |
| Dec 2022 | 0 | -41,335,878 | -30,930,647 | 62,028,518 | 9,826,930 | 52,201,588 | -27,220,345 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.24
Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.50 · spot: $0.95 · call volume: 2 · put volume: 20Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | $115.27M | $1.72 | — |
| LENZ | LENZ Therapeutics, Inc. | $109.97M | $3.50 | — |
| MOLN | MOLECULAR PARTNERS AG | $109.55M | $2.86 | — |
| CMPX | Compass Therapeutics, Inc. | $109.26M | $0.61 | — |
| FATE | FATE THERAPEUTICS INC | $124.00M | $1.02 | — |
News headlines (Yahoo Finance, 1h cache)
Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC
2026-11-03 22:00 · Yahoo
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
2026-09-23 10:00 · Yahoo
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
2026-09-16 11:27 · Yahoo
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
2026-09-10 21:00 · Yahoo
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 11:27 · Yahoo
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
2026-08-25 13:40 · Yahoo
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
2026-08-24 16:00 · Yahoo
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
2026-08-12 12:01 · Yahoo
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
2026-09-14 13:30 · Yahoo
Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?
2026-09-10 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.